Fundamentally Strong Pharma Stock Trading at a Discount of 34% to Keep an Eye On

Synopsis: Caplin Point Laboratories Limited, a small-cap pharma firm, is trading at a 34.36% discount from its 52-week high, attracting attention due to consistent growth, strong returns, and upcoming expansion plans.

This Small-cap Pharma Stock, engaged in manufacturing, developing, and exporting generic pharmaceuticals, including formulations, injectables, and softgel capsules across regulated and emerging global markets, is in focus after the stock is currently trading at a discount of 34.36 percent.

With a market capitalization of Rs. 11,949.04 crore, the shares of Caplin Point Laboratories Limited closed at Rs. 1,572 per equity share, down nearly 2.03 percent from its previous day’s close price of Rs. 1,570.10. 

Over the past five years, the stock has provided impressive returns of more than 245 percent.  The stock is currently trading at a 34.36 percent discount from its 52-week high of Rs. 2,395 per equity share.

Company Overview:

Caplin Point Laboratories Limited was founded in 1990 and is an Indian pharmaceutical company headquartered in Chennai, Tamil Nadu. It develops, manufactures, and exports a wide range of generic medicines, focusing primarily on Latin American, African, and emerging Asian markets. The firm is known for its cost-efficient supply chain and vertically integrated operations.

Caplin Point Laboratories Limited produces a broad portfolio that includes tablets, capsules, topical creams, injectables, and oral liquids. Its subsidiary, Caplin Steriles Limited, specializes in sterile injectables for regulated markets such as the United States and Europe. Research and development efforts focus on affordable formulations and backward integration to ensure quality and supply security.

Capex and Strategic Investments

Caplin Point Laboratories Limited has planned major investments to grow its business. Key projects include Caplin Plant I and the API facility upgradation, both already completed. The Oncology Facility at Kakallur is also completed, while the Oncology API Facility in Chennai and the OSD Facility in Puducherry are expected by Q3 FY27. The COL Injectable Facility in Gummidipoondi is planned for completion by Q4 FY27.

The company has set aside over Rs. 1,000 crores for these projects, with nearly half already completed. The remaining investment will be made over the next 2–3 years. These investments will increase production capacity, expand the product range, and support backward integration. 

Product Portfolio

Caplin Point Laboratories Limited has a strong and diverse product portfolio. It offers over 5,000 registered products and more than 650 pharmaceutical formulations. The company serves 36 different therapeutic segments. Its product mix also covers over 65% of the WHO essential drug list, showing its wide reach and importance in healthcare.

Manufacturing and R&D Facilities

Caplin Point Laboratories Limited has a strong manufacturing and R&D platform in India. Its facilities are mainly located in Tamil Nadu, Puducherry, and Andhra Pradesh. The company operates multiple plants in Chennai, Gummidipoondi, and Visakhapatnam. It also has dedicated research and development units, ensuring quality production and continuous innovation in pharmaceutical products.

Expansion of New Global Markets:

Caplin Point Laboratories Limited plans to expand into new global markets. It aims to enter regulated regions like Canada, Australia, MENA, and Russia/CIS. The company also plans to grow in major Latin American markets such as Mexico and Brazil in the near to medium term.

Recent Quarter Results:

Coming into financial highlights, Caplin Point Laboratories Limited’s revenue has increased from Rs. 493 crore in Q3 FY25 to Rs. 543 crore in Q3 FY26, which has grown by 10.14 percent. The net profit has also grown by 18.57 percent from Rs. 140 crore in Q3 FY25 to Rs. 166 crore in Q3 FY26.

Caplin Point Laboratories Limited’s revenue and net profit have grown at a CAGR of 17.55 percent and 20.27 percent, respectively, over the last five years.

In terms of return ratios, the company’s ROCE and ROE stand at 25.8 percent and 22.7 percent, respectively. Caplin Point Laboratories Limited has an earnings per share (EPS) of Rs. 80.7, and is an almost debt-free company, with borrowings amounting to Rs. 5 crore.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Fundamentally Strong Pharma Stock Trading at a Discount of 34% to Keep an Eye On appeared first on Trade Brains.